Rechercher un essai clinique
Autre(s) option(s) de recherche
24 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
EORTC 26082-22081: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed Glioblastoma without methylation of the MGMT gene promoter - A randomized multicenter, open-label, phase II study - DE
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
NOA-20/Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL
Neurologische Universitätsklinik Heidelberg
Abteilung für Neuroonkologie
ALLEMAGNE
Baden-Württemberg
HEIDELBERG
STORM: A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
ALLEMAGNE
Berlin
BERLIN
Temsirolimus in PZNSL: Phase II study to investigate the efficacy of Temsirolimus in refractory and recurrent Primary CNS Lymphoma after initial chemotherapy with a high-dose Methotrexate
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie (CCM)
ALLEMAGNE
Berlin
BERLIN
Phase I/II study with Bendamustine and Temsirolimus in patients with relapsed or refractory Mantle Cell Lymphoma not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation - DE
Vivantes Klinikum Am Urban
Abteilung Innere Medizin - Hämatologie und Onkologie
ALLEMAGNE
Hessen
FRANKFURT AM MAIN
TOR-AML: A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of Temsirolimus added to standard primary therapy in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML)
Universitätsklinikum Frankfurt
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
ALLEMAGNE
Niedersachsen
HANNOVER
TEMHEAD: A Single Arm, open-label multicentre phase II trial of Temsirolimus in patients with relapsed/recurrent Squamous Cell Cancer of the Head and Neck (HNSCC) - DE
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
ALLEMAGNE
Nordrhein-Westfalen
AACHEN
A randomized phase 4 study comparing 2 intravenous temsirolimus regimens in subjects with relapsed, refractory mantle cell lymphoma - DE
Universitätsklinikum Aachen
Klinik für Onkologie, Hämatologie und Stammzelltransplantation (Med. Klinik IV)
ALLEMAGNE
Rheinland-Pfalz
MAINZ
A randomized phase 4 study comparing 2 intravenous temsirolimus regimens in subjects with relapsed, refractory mantle cell lymphoma - DE
Universitätsmedizin Mainz
III. Medizinische Klinik und Poliklinik
ALLEMAGNE
Sachsen
DRESDEN
TEMDS (TUD-TEMDS1-042): Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study (Phase II) - Terminated
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
BELGIQUE
ANTWERPEN
ANTWERPEN
INTORACT : Phase 3b, randomized, open-label study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma - BE
Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim
Oncologie
BELGIQUE
VLAAMS BRABANT
LEUVEN
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter - a randomized multicenter, open-label, Phase II study - BE
UZ Leuven - Campus Gasthuisberg
Dienst neurologie/ Department of Neurology
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Institution: Information not provided - CA
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma (Completed)
Institution: Information not provided - CA
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
INTORACT : Phase 3b, randomized, open-label study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma - ES (Completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
INTORSECT: A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy (Phase III) - ES (completed)
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy - ES (Completed)
Institution: Information not provided - ES
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude de phase IV, randomisée, comparant 2 schémas du Temsirolimus en intraveineux chez des patients présentant un lymphome des cellules du manteau en rechute, réfractaire.
Institution: Information not provided - FR
FRANCE
ILE-DE-FRANCE
CRÉTEIL
Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d'efficacité du Torisel® (Temsirolimus);
Hôpitaux Universitaires Henri Mondor
Service d'Hépatologie
FRANCE
ILE-DE-FRANCE
PARIS
Etude randomisée, multicentrique, en ouvert, de phase II, comparant la radiothérapie avec administration concomitante et adjuvante de temsirolimus (CCI-779) et la chimioradiothérapie par témozolomide dans le glioblastome de diagnostic récent sans méthylation du promoteur du gène de la MGMT
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Service de Neurologie 2 : Unité d'Onco-Neurologie
ROYAUME-UNI
Devon
PLYMOUTH
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Brutons Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (phase III) - UK
Plymouth Derriford Hospital
British National Lymphoma Institute Research Group
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
EORTC 26082 - 22081: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter - a randomized multicenter, open-label, Phase II study - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK
INTORACT : Phase 3b, randomized, open-label study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma - UK
Institution: Information not provided - UK
ROYAUME-UNI
Greater Manchester
ADDRESS: NOT PROVIDED - UK